BR0209652A - Derivados de dipeptìdeos possuindo um grupo 2-tioacila n-terminal, como inibidores de vasopeptidase - Google Patents

Derivados de dipeptìdeos possuindo um grupo 2-tioacila n-terminal, como inibidores de vasopeptidase

Info

Publication number
BR0209652A
BR0209652A BR0209652-8A BR0209652A BR0209652A BR 0209652 A BR0209652 A BR 0209652A BR 0209652 A BR0209652 A BR 0209652A BR 0209652 A BR0209652 A BR 0209652A
Authority
BR
Brazil
Prior art keywords
terminal
dipeptide derivatives
thioacyl group
vasopeptidase inhibitors
inhibitors
Prior art date
Application number
BR0209652-8A
Other languages
English (en)
Inventor
Anne Cynthia Fink
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0209652A publication Critical patent/BR0209652A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"DERIVADOS DE DIPEPTìDEOS POSSUINDO UM GRUPO 2-TIOACILA N-TERMINAL, COMO INIBIDORES DE VASOPEPTIDASE". A presente invenção refere-se a compostos da fórmula: onde R, R~ 1~, COOR~ 2~, R~ 3~-R~ 7~, alk e X possuem o significado como acima, sendo úteis como inibidores duplos de enzima de conversão de angiotensina e endopeptidase neutra, bem como inibidores de enzima de conversão de endotelina.
BR0209652-8A 2001-05-15 2002-05-14 Derivados de dipeptìdeos possuindo um grupo 2-tioacila n-terminal, como inibidores de vasopeptidase BR0209652A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29108801P 2001-05-15 2001-05-15
US33957501P 2001-12-11 2001-12-11
PCT/EP2002/005293 WO2002092622A2 (en) 2001-05-15 2002-05-14 Dipeptide derivatives having a n-terminal 2-thioacyl group as vasopeptidase inhibitors

Publications (1)

Publication Number Publication Date
BR0209652A true BR0209652A (pt) 2004-07-13

Family

ID=26966569

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0209652-8A BR0209652A (pt) 2001-05-15 2002-05-14 Derivados de dipeptìdeos possuindo um grupo 2-tioacila n-terminal, como inibidores de vasopeptidase

Country Status (23)

Country Link
US (3) US6777443B2 (pt)
EP (2) EP2239268A1 (pt)
JP (1) JP4390458B2 (pt)
KR (1) KR100908152B1 (pt)
CN (1) CN1649893A (pt)
AR (1) AR035890A1 (pt)
AU (1) AU2002314067B2 (pt)
BR (1) BR0209652A (pt)
CA (1) CA2449292A1 (pt)
CO (1) CO5540347A2 (pt)
CZ (1) CZ20033077A3 (pt)
HU (1) HUP0304084A3 (pt)
IL (1) IL158772A0 (pt)
MX (1) MXPA03010403A (pt)
MY (1) MY127495A (pt)
NO (1) NO20035084L (pt)
NZ (1) NZ529438A (pt)
PE (1) PE20030042A1 (pt)
PL (1) PL366786A1 (pt)
RU (1) RU2298559C2 (pt)
SK (1) SK14032003A3 (pt)
TW (1) TWI295996B (pt)
WO (1) WO2002092622A2 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777443B2 (en) * 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives
US7199261B2 (en) * 2001-07-06 2007-04-03 Teva Pharmaceutical Industries Ltd Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives
ATE342261T1 (de) * 2001-09-21 2006-11-15 Novartis Pharma Gmbh Pyranderivate als inhibitoren von ace und nep
DE60315795T2 (de) * 2002-01-17 2008-06-05 Novartis Ag Pharmazeutische zusammensetzung enthaltend valsartan und nep-inhibitoren
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
SI1515717T1 (sl) * 2002-06-13 2009-02-28 Novartis Ag Kalcijeve soli statinov, izvedenih iz indola
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
EP1827448A1 (en) * 2004-12-15 2007-09-05 Solvay Pharmaceuticals GmbH Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and hmg coa reductase inhibitors
EP1858518A1 (en) * 2005-03-14 2007-11-28 Orion Corporation A combination treatment for enhancing diuresis
US7390789B2 (en) * 2005-09-13 2008-06-24 William H Simmons Thio-containing inhibitors of aminopeptidase P, and compositions thereof
US7400236B2 (en) 2005-10-21 2008-07-15 Gm Global Technology Operations, Inc. Vehicular lane monitoring system utilizing front and rear cameras
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
US20120157387A1 (en) * 2006-11-28 2012-06-21 Apotex Technologies Inc. Orally bioavailable d-gamma-glutamyl-d-tryptophan
TW200838501A (en) 2007-02-02 2008-10-01 Theravance Inc Dual-acting antihypertensive agents
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
TWI406850B (zh) 2007-06-05 2013-09-01 Theravance Inc 雙效苯并咪唑抗高血壓劑
US7834041B2 (en) 2007-09-07 2010-11-16 Theravance, Inc. Dual-acting antihypertensive agents
JP2011506459A (ja) 2007-12-11 2011-03-03 セラヴァンス， インコーポレーテッド 抗高血圧剤としての二重作用性ベンゾイミダゾール誘導体およびその使用
WO2009134741A1 (en) 2008-04-29 2009-11-05 Theravance, Inc. Dual-acting antihypertensive agents
US7863309B2 (en) 2008-07-24 2011-01-04 Theravance, Inc. Dual-acting antihypertensive agents
WO2011005674A1 (en) 2009-07-07 2011-01-13 Theravance, Inc. Dual-acting pyrazole antihypertensive agents
ES2441419T3 (es) 2009-07-22 2014-02-04 Theravance, Inc. Agentes antihipertensivos de doble acción basados en oxazol
WO2011090929A1 (en) 2010-01-19 2011-07-28 Theravance, Inc. Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
US20150011484A1 (en) * 2011-03-31 2015-01-08 Aptoex Technologies, Inc. Prodrugs of d-gamma-glutamyl-d-tryptophan and d-gamma-glutamyl-l-tryptophan
US9212206B1 (en) * 2014-11-24 2015-12-15 William H Simmons 4-Fluoro-Thio-containing inhibitors of APP2, compositions thereof and method of use
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
WO2019213386A1 (en) * 2018-05-04 2019-11-07 New Mexico Tech University Research Park Corporation Proteasome inhibitors
CN113956183B (zh) * 2021-10-28 2023-06-20 成都市科隆化学品有限公司 一种Boc-Ser(Bzl)-OH及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6733190A (en) 1989-11-27 1991-06-26 Santen Pharmaceutical Co. Ltd. Amino acid derivative
FR2679564A1 (fr) 1991-07-23 1993-01-29 Inst Nat Sante Rech Med Nouveaux acylmercaptoalcanoldipeptides, leur preparation et les compositions qui les contiennent.
ES2108855T3 (es) 1992-07-21 1998-01-01 Ciba Geigy Ag Derivados de acido oxamico como agentes hipocolesteremicos.
US5432186A (en) * 1993-11-16 1995-07-11 Ciba-Geigy Corporation Cyclic amino acid derivatives
US5508266A (en) 1994-06-22 1996-04-16 Ciba-Geigy Corporation Gem-disubstituted amino acid derivatives
US6162828A (en) 1995-03-31 2000-12-19 Takeda Chemical Industries, Ltd. Cysteine protease inhibitor
DE69632821T2 (de) * 1995-04-25 2005-08-25 Daiichi Fine Chemical Co., Ltd., Takaoka In wasser hochlöslicher metalloproteinase-inhibitor
DE69627483T2 (de) 1995-05-10 2004-04-01 Darwin Discovery Ltd., Slough Peptidartige stoffe, die metalloproteinasen und die tnf-freisetzung hemmen, und ihre therapeutische verwendung
JPH11507352A (ja) * 1995-06-07 1999-06-29 ジンタ・インコーポレイテッド 新規カルバメート基本カチオン性脂質
US6245809B1 (en) * 1996-12-09 2001-06-12 Cor Therapeutics Inc. Integrin antagonists
US6492421B1 (en) * 1997-07-31 2002-12-10 Athena Neurosciences, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
DE19745151A1 (de) 1997-10-14 1999-04-15 Basf Ag Neue Verbindungen zur Behandlung von Krankheiten, die mit der biologischen Wirkung von Endothelin assoziiert sind
FR2770844A1 (fr) 1997-11-10 1999-05-14 Inst Nat Sante Rech Med Inhibiteurs de toxines clostridiales et compositions pharmaceutiques les contenant
EP1030853A1 (en) * 1997-11-12 2000-08-30 Ariad Pharmaceuticals, Inc. Novel signal transduction inhibitors, compositions containing them
RU2000129510A (ru) 1998-04-23 2002-11-10 Новартис АГ (CH) Определенные тиольные ингибиторы эндотелинпревращающих ферментов
JP3646062B2 (ja) 1998-04-23 2005-05-11 ノバルティス アクチエンゲゼルシャフト エンドセリン変換酵素のヘテロアリール置換チオール型阻害剤
ES2188277T3 (es) 1998-12-31 2003-06-16 Aventis Pharma Inc Inhibidores selectivos de mmp-12.
FR2788526B1 (fr) 1999-01-20 2002-07-05 Inst Nat Sante Rech Med Composes tripeptidiques utiles a titre d'hinhibiteurs selectifs de l'aminopeptidase a et compositions pharmaceutiques correspondantes
CO5160290A1 (es) 1999-03-29 2002-05-30 Novartis Ag Derivados de acido fenoxifeniloxamico sustituido .
US6503949B1 (en) * 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
GB9917909D0 (en) * 1999-07-31 1999-09-29 Synphar Lab Inc Cysteine protease inhibitors
CA2383002A1 (en) * 1999-08-27 2001-03-08 Cytovia, Inc. Substituted .alpha.-hydroxy acid caspase inhibitors and the use thereof
US6803383B2 (en) * 2000-03-27 2004-10-12 The Scripps Research Institute Inhibition of angiogenesis and tumor growth
CA2405496A1 (en) 2000-04-03 2001-10-11 Richard A. Reeves Vasopeptidase inhibitors to treat isolated systolic hypertension
SK14612002A3 (sk) 2000-04-12 2003-05-02 Novartis Ag Farmaceutická kompozícia obsahujúca inhibítor aldosterónsyntázy prípadne v kombinácii s antagonistom AT1-receptora a jej použitie
US20020013307A1 (en) 2000-05-23 2002-01-31 Pablo Lapuerta Use of vasopeptidase inhibitors to treat or slow the progression of cognitive dysfunction and to treat and/or prevent dementia
US6777443B2 (en) * 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives

Also Published As

Publication number Publication date
US6777443B2 (en) 2004-08-17
AU2002314067B2 (en) 2006-03-16
SK14032003A3 (sk) 2004-06-08
JP4390458B2 (ja) 2009-12-24
KR100908152B1 (ko) 2009-07-16
HUP0304084A3 (en) 2010-10-28
WO2002092622A3 (en) 2003-04-10
EP1392720A2 (en) 2004-03-03
WO2002092622A8 (en) 2004-01-22
US20040235754A1 (en) 2004-11-25
EP2239268A1 (en) 2010-10-13
MXPA03010403A (es) 2004-03-09
KR20030096401A (ko) 2003-12-24
MY127495A (en) 2006-12-29
CZ20033077A3 (cs) 2004-02-18
JP2005504011A (ja) 2005-02-10
TWI295996B (en) 2008-04-21
PE20030042A1 (es) 2003-02-28
PL366786A1 (en) 2005-02-07
US20020183260A1 (en) 2002-12-05
IL158772A0 (en) 2004-05-12
CO5540347A2 (es) 2005-07-29
US20060058242A1 (en) 2006-03-16
RU2298559C2 (ru) 2007-05-10
WO2002092622A2 (en) 2002-11-21
US6992105B2 (en) 2006-01-31
HUP0304084A2 (hu) 2004-12-28
NO20035084L (no) 2004-01-15
NZ529438A (en) 2005-07-29
NO20035084D0 (no) 2003-11-14
AR035890A1 (es) 2004-07-21
CA2449292A1 (en) 2002-11-21
CN1649893A (zh) 2005-08-03
RU2003134153A (ru) 2005-06-10

Similar Documents

Publication Publication Date Title
BR0209652A (pt) Derivados de dipeptìdeos possuindo um grupo 2-tioacila n-terminal, como inibidores de vasopeptidase
BR0309281A (pt) Triaril-oxi-espiro-pirimidino-2,4,6-trionas inibidoras de metaloproteinases
ATE226193T1 (de) Substituierte zyklische amine als metalloproteaseinhibitoren
BR0108396A (pt) Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
DE60140695D1 (de) Anilinopyrimidinderivate als ikk?inhibitoren, und hiermit in zusammenhang stehende zusammensetzungen und verfahren
AU5414000A (en) Compounds
BR0009610A (pt) Inibidores de caspase e uso dos mesmos
WO2002030944A3 (en) Fluorescent nucleobase conjugates having anionic linkers
BR0109588A (pt) Inibidores de caspase de carbamato e usos destes
ATE253545T1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
ATE326454T1 (de) Neue bernsteinsäure derivative als cysteine- protease-inhibitoren
PT1001930E (pt) Derivados de n-hidroxiformamida como inibidores de metaloproteinases de matriz
ATE232873T1 (de) Phosphonsaürederivate als ptp-1b-inhibitoren
DK1273299T3 (da) Minoxidilinindeholdende praparater
BR0206501A (pt) Inibidores de cruzipaìna e outras cisteìna proteases
PA8521801A1 (es) Derivados de ciclopentil-glutaramida como inhibidores de endopeptidasa neutra
ATE309264T1 (de) Peptidyl-2-amino-1hydroxyalkansulfonsäuren als cystein-protease-inhibitoren
AU2001275346A1 (en) Compositions, kits, and methods for identification and modulation of type i diabetes
BR0212535A (pt) Compostos e composições como inibidores de catepsina
BR9909805A (pt) Certos inibidores de tiol de enzima de conversão de endotelina
BR0014990A (pt) Derivados de tetrahidrotiopirano ranftalazinona como inibidores de pde4
DE60134230D1 (de) Substraten und nachweise zur wirksamkeit von beta-secretase
BR0115996A (pt) Sulfamidotienopirimidinas
ATE288922T1 (de) Bestimmte heteroaryl substituierte thiol inhibitoren von endothelin wechselnden enzymen
TW200407325A (en) Novel interleukin-1β converting enzyme inhibitors

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUI DADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 10A ANUIDADE.